The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge
Executive Summary
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.
You may also be interested in...
Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention
Office of Inspector General analysis could add momentum to reforms of the rebating system.
Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention
Office of Inspector General analysis could add momentum to reforms of the rebating system.
US FDA Outlines Biosimilar First Interchangeability Policy … In A Memo
Stakeholders may be irked that the agency chose to release a memo on its interpretation of the first interchangeable exclusivity law before issuing formal guidance.